Andrew Marr assesses the impact of the of the EMA announcement of 1 July 2011 on the mandatory provision of medicinal product information (EVMPD) by 2 July 2012. This article originally appeared on www.regulatoryaffairspharma.com.
Please click here to find more information: Andrew Marr assesses the impact of the EMA announcement on Medicinal Product Information
No comments:
Post a Comment